Novartis Approves 5.7% Dividend Increase to CHF 3.70 Per Share for 2025
Novartis AG announced at its March 6, 2026 AGM a 5.7% dividend increase to CHF 3.70 per share for 2025, marking the 29th consecutive annual increase with a 3.0% yield, payable from March 12, 2026.
Novartis AG announced at the AGM held on March 6, 2026, approved dividend increase of 5.7% to CHF 3.70 per share for 2025. Shareholders approved the 29th consecutive increase, resulting in a dividend yield of 3.0%. Payment of the 2025 dividend will be made from March 12, 2026.
The company's share price is now at CHF 130.5, with a 30 day share price return of 13.85% and a year to date share price return of 20.28%. The 1 year total shareholder return of 36.64% and 5 year total shareholder return of 103.83% point to momentum that has been building rather than fading.
Novartis' robust pipeline and rapid regulatory progress in advanced therapies, including biologics, gene, and cell therapies, positions the company to benefit from emerging healthcare technologies, potentially accelerating future earnings and margin growth as new high-value products launch.